- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | MAIA Biotechnology, Inc.: MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market | 138 | GlobeNewswire (Europe) | Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine... ► Artikel lesen | |
| 20.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 445 | GlobeNewswire (Europe) | High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine... ► Artikel lesen | |
| 13.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 298 | GlobeNewswire (Europe) | Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)... ► Artikel lesen | |
| 16.12.25 | MAIA Biotechnology announces $1.51M private placement | 2 | Seeking Alpha | ||
| 16.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $1.51 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | 207 | GlobeNewswire (Europe) | CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA),... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer | 419 | GlobeNewswire (Europe) | Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential | 4 | GlobeNewswire (USA) | ||
| 10.12.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | MAIA Biotechnology, Inc.: MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach | 144 | GlobeNewswire (Europe) | CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) - The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade... ► Artikel lesen | |
| 01.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Directors | 1 | GlobeNewswire (USA) | ||
| 21.11.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 | 317 | GlobeNewswire (Europe) | Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO, Nov. 21, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 20.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Maia Biotechnology stellt Studiendaten auf der SITC-Konferenz 2025 vor | 1 | Investing.com Deutsch | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 125,66 | -0,33 % | Gilead Sciences schlägt zu - 68 Prozent Aufschlag | Die US-amerikanische Biotech-Gesellschaft Gilead Sciences will sich im Bereich der Onkologie verstärken. Mit der geplanten Übernahme von Arcellx erwirbt das Unternehmen die volle Kontrolle über eine... ► Artikel lesen | |
| ABBVIE | 196,00 | -0,31 % | Rekordquartal und AbbVie-Deal beflügeln Gubra-Aktie: Kursplus von 13,88 % | ||
| ABBOTT LABORATORIES | 98,07 | -0,38 % | Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval | ||
| SCHOTT PHARMA | 14,780 | -0,67 % | SCHOTT PHARMA AG & CO KGAA - Stabilität trifft Perspektive | ||
| EDWARDS LIFESCIENCES | 73,30 | +0,14 % | Edwards Lifesciences Corp - 10-K, Annual Report | ||
| ASSEMBLY BIOSCIENCES | 25,200 | 0,00 % | Assembly Biosciences: Top-Favorit 2026 - darum bin ich wieder voll dabei! | Alte Liebe rostet nicht: Nach zwischenzeitlich +412% Kursgewinn im vergangenen Jahr und massiven Gewinnmitnahmen habe ich mich als Ex-Großaktionär erneut in erheblichem Umfang bei Assembly Biosciences... ► Artikel lesen | |
| PENTIXAPHARM | 2,055 | -1,67 % | EQS-News: Pentixapharm Holding AG: Amerikanische Bundesgesundheitsbehörde FDA erteilt Freigabe für klinische Phase I/II-Studie für CXCR4-basiertes hämatoonkologisches Entwicklungsprogramm | EQS-News: Pentixapharm Holding AG
/ Schlagwort(e): Studie
Amerikanische Bundesgesundheitsbehörde FDA erteilt Freigabe für klinische Phase I/II-Studie für CXCR4-basiertes hämatoonkologisches... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,923 | -0,54 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 139,40 | +0,47 % | Axsome Therapeutics auf Oppenheimer-Konferenz: Wachstumsstrategie im Fokus | ||
| MEDPACE | 378,10 | -1,10 % | Zelluna ASA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial | Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA... ► Artikel lesen | |
| ZEALAND PHARMA | 49,290 | +0,59 % | Zealand Pharma A/S: Zealand Pharma Announces Financial Results for the Full Year 2025 | Company announcement - No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide... ► Artikel lesen | |
| UNITED THERAPEUTICS | 426,00 | -0,02 % | H.C. Wainwright raises United Therapeutics stock price target to $600 | ||
| UCB | 250,90 | -0,12 % | UCB Full-year Profit, Sales Jump: Issues Upbeat Outlook | BRUSSELS (dpa-AFX) - UCB SA (UCBJY) on Thursday reported a 46% increase in full-year profit, supported by a 32% rise in sales.Profit before income taxes increased 57% to €1.822 billion from... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 368,80 | +0,82 % | H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating at buy | ||
| BRIDGEBIO PHARMA | 55,90 | -0,64 % | BridgeBio Pharma, Inc.: BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates | $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio... ► Artikel lesen |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,040 (+1,83 %) liegt der Kurs bei 2,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.